GABRE as a Radioligand Therapy Target
GABRE, gamma-aminobutyric acid type A receptor subunit epsilon, is a cell-surface protein (membrane receptor). In Human Protein Atlas immunohistochemistry, GABRE staining is highest in colorectal cancer (100% of samples positive), kidney cancer (100% of samples positive) and gastric cancer (100% of samples positive). Evidence on whether GABRE internalizes is mixed. Clinical status: Clinical-stage (up to phase 3, any modality).
Is GABRE a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in colorectal cancer, 100% of samples positive.
- ⚠️ Internalization: Mixed evidence.
- ✅ Clinical precedent: Clinical-stage (up to phase 3, any modality)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
GABRE expression in cancer
Protein expression of GABRE across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Colorectal Cancer | 1.00 | High | 100% |
| Kidney Cancer | 0.94 | High | 100% |
| Gastric Cancer | 0.87 | High | 100% |
| Pancreatic Cancer | 0.81 | High | 100% |
| Melanoma | 0.81 | High | 100% |
| Thyroid Cancer | 0.75 | High | 100% |
| Breast Cancer | 0.70 | High | 100% |
| Ovarian Cancer | 0.67 | High | 100% |
| Lung Cancer | 0.67 | High | 91% |
| Endometrial Cancer | 0.64 | High | 92% |
| Bladder Cancer | 0.61 | High | 82% |
| Neuroendocrine Tumors | 0.58 | High | 100% |
| Liver Cancer | 0.56 | High | 67% |
| Head and Neck Cancer | 0.50 | Medium | 100% |
| Cervical Cancer | 0.50 | Medium | 90% |
| Prostate Cancer | 0.47 | Medium | 90% |
| Testicular Cancer | 0.46 | Medium | 91% |
| Skin Cancer | 0.37 | Medium | 78% |
| Lymphoma | 0.33 | Medium | 64% |
| Glioma | 0.30 | Medium | 60% |
Is GABRE internalized?
Uncertain. Insufficient literature found.
GABRE clinical trials
Clinical-stage (up to phase 3, any modality). Nuclens hasn't indexed trials for GABRE yet. Search ClinicalTrials.gov for GABRE trials.
GABRE normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See GABRE in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
GABRE gene essentiality (DepMap)
CRISPR knockout effect across 1255 cancer cell lines: 0.14 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related colorectal cancer radioligand targets
c-MET (MET) · HER3 (ERBB3) · FAP · EGFR · CEA (CEACAM5) · EPCAM · SSTR2 · STEAP2
See all radioligand therapy targets in colorectal cancer.
See how GABRE ranks against 15,000 targets for your indication.
Run a free analysisData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.